Yiyi Chen

Associate Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yiyi Chen is an Associate Professor at Oregon Health & Science University in the United States. Her research focuses on pediatric urology, cancer treatment efficacy, and the molecular mechanisms of disease, as demonstrated in her recent articles. Dr. Chen has contributed to studies on gender equity in healthcare, the effectiveness of various treatments for cancer, and the implications of surgical practice trends in urology.

Articles (10)

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Jiaoti Huang

Professor and Chairman

Duke Medicine

UNITED STATES

View details

Emile Latour

Oregon Health & Science University

UNITED STATES

View details

Yoshinobu Koguchi

Associate Professor (Research)

Ohio State University

UNITED STATES

View details

Ryan Kopp

Assistant Professor

Oregon Health & Science University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yiyi Chen

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Perceptions of gender equity in pediatric urology

Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis.

The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity.

"Was It Worth It?": A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy.

Relative value units do not adequately account for operative time in pediatric urology.

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.

Smoking history and cessation discussions in cancer patients receiving definitive radiotherapy: Do we treat all patients equally?

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.

RUC Operative Time Estimates are Inaccurate, Resulting in Decreased Work RVU Assignments for Longer Urologic Procedures.

Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.

Collaborators (4)

Jiaoti Huang

Emile Latour

Yoshinobu Koguchi

Ryan Kopp

Make your next move.